['pneumonia', 'pneumococcal infections']
['cal02 low-dose', 'cal02 high-dose', 'placebo']

        Inclusion Criteria:

          -  Adult male or female patients ≥ 18 years and ≤ 80 years of age

          -  Body weight 40-140 kg

          -  Severe pneumonia caused by Streptococcus pneumoniae managed in an ICU

          -  CURB-65 score ≥ 3 in patients aged > 65 and CURB-65 ≥ 2 in patients aged < 65

          -  Streptococcus pneumoniae identification with the urine antigen test or any other
             proven documented identification method

          -  Written informed consent provided by the patient, the relatives or the designated
             trusted person and/or according to local guidelines

        Exclusion Criteria:

          -  Patients with hospital-acquired-, health care-acquired- or ventilator-
             associated-pneumonia

          -  More than (i) 12 hours since diagnosis of severe CAPP and (ii) 24 hours or 60 hours
             since antibiotic treatment IV or per os, respectively, unless documented not to be
             active against S. pneumoniae, will have elapsed at the time of IMP administration

          -  APACHE II score > 30 points

          -  SOFA score > 12 points

          -  Inability to maintain a mean arterial pressure ≥ 50 mm Hg

          -  Known hypersensitivity to liposomal formulations

          -  Patients with severe neutropenia or lymphoma or current or anticipated chemotherapy

          -  End-stage neuromuscular disorders

          -  Patients who have long-term tracheostomy

          -  Current or recent participation in an investigational study

          -  Presence of other pneumococcal site infection

          -  Patients with known acquired immune deficiency syndrome (AIDS) with CD4 count < 200
             cells/mL

          -  Patients with known post-obstructive pneumonia (active primary lung cancer or another
             malignancy metastatic to the lungs)

          -  Patients with cystic fibrosis, Pneumocystis jiroveci pneumonia, or active tuberculosis

          -  Patients receiving immunosuppressant therapy

          -  Patients with a known liver function deficiency

          -  Splenectomised patients

          -  Patients who have experienced an allergic reaction to eggs

          -  Moribund clinical condition

          -  Nursing and pregnant women

          -  Women of child bearing potential not using an effective contraception.
      